Emulate, Inc.

Emulate, Inc.
Name	Emulate, Inc.
Industry	Biotechnology
Founded	2013
Founders	Don Ingber; Geraldine A. Hamilton
Headquarters	Boston, Massachusetts
Products	Organ-Chips; S-1 filing; laboratory services

Emulate, Inc. is a biotechnology company that develops microengineered organ-on-chip platforms intended to model human physiology and disease. The company integrates microfluidics, tissue engineering, and stem cell biology to create in vitro systems aimed at improving drug discovery, toxicology testing, and personalized medicine. Emulate’s platforms have been used in academic research, pharmaceutical development, and regulatory science.

History

Emulate was founded in 2013 by Don Ingber and Geraldine A. Hamilton following work at the Wyss Institute for Biologically Inspired Engineering, Harvard University, and collaborations with Boston-area academic institutions including Massachusetts Institute of Technology, Harvard Medical School, and Brigham and Women’s Hospital. Early milestones included commercializing organ-on-chip concepts demonstrated in peer-reviewed journals and forging partnerships with biotechnology companies such as Amgen, Roche, and Janssen, as well as government laboratories like the National Institutes of Health and Defense Advanced Research Projects Agency. Corporate developments involved venture financing rounds with investors including ARCH Venture Partners, Polaris Partners, and Casdin Capital, and public filings culminating in a U.S. securities offering. The company expanded operations with facilities in Boston, San Francisco, and collaborations that connected to research hubs like the Broad Institute and Salk Institute.

Technology and Products

Emulate’s core technology centers on microfluidic Organ-Chips that recapitulate structural, mechanical, and biochemical features of human organs. The platform combines microfabrication techniques used in semiconductor industries, cell sourcing from induced pluripotent stem cell programs linked to Stanford University and Columbia University, and extracellular matrix designs informed by research from Johns Hopkins University and University of California, San Francisco. Product lines include organ-specific chips for Liver, Lung, Gut, Kidney, Blood-Brain Barrier, and Multi-Organ formats, integrated with imaging workflows compatible with instruments from Thermo Fisher Scientific, Agilent Technologies, and PerkinElmer. Software and data solutions link to laboratory information management systems utilized by Pfizer, Merck, and Novartis to support translational research, while assay development aligns with protocols cited by the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare products Regulatory Agency.

Research and Collaborations

Emulate has collaborated with academic centers such as Massachusetts General Hospital, Yale School of Medicine, University of Pennsylvania, and University of Cambridge to validate models for infectious disease, oncology, and immunology. Partnerships with pharmaceutical companies including GlaxoSmithKline, AstraZeneca, and Bristol Myers Squibb focused on pharmacokinetics, pharmacodynamics, and safety assessment. Cooperative agreements with nonprofit organizations like the Bill & Melinda Gates Foundation and Gates-funded initiatives targeted tropical disease modeling, while work with DARPA and the Biomedical Advanced Research and Development Authority connected the technology to biodefense and pandemic preparedness efforts. Cross-disciplinary projects involved researchers from Cold Spring Harbor Laboratory, Scripps Research, and the Max Planck Institute.

Business and Funding

Emulate’s financing history includes seed investment, multiple venture capital rounds, strategic corporate partnerships with Johnson & Johnson and Takeda, and a public equity offering overseen under securities regulators including the U.S. Securities and Exchange Commission. Revenue streams have encompassed instrument sales, consumables, custom assay services for biotechnology firms like Regeneron and Biogen, and collaborative research agreements with academic consortia such as the Human Cell Atlas initiative. Business strategy included scaling manufacturing with contract manufacturers in the Boston area, supply-chain partnerships with logistics providers serving research institutions like the Karolinska Institutet and Imperial College London, and engagement with health technology investors such as Sequoia Capital and 8VC.

Regulatory and Ethical Considerations

Emulate’s platforms intersect with regulatory science initiatives at the U.S. Food and Drug Administration, European Commission research programs, and the International Council for Harmonisation. Discussions with the FDA’s Center for Drug Evaluation and Research and the National Toxicology Program addressed validation pathways, good laboratory practice alignment, and potential qualification as alternative methods to animal testing under frameworks promoted by the Organisation for Economic Co-operation and Development. Ethical considerations engaged bioethics scholars at institutions like the Hastings Center, the Nuffield Council on Bioethics, and the Wellcome Trust, focusing on human tissue sourcing, consent models related to biobanks at the UK Biobank and All of Us Research Program, and implications for clinical trial design overseen by Institutional Review Boards at Columbia University and Stanford.

Impact and Applications

Emulate’s Organ-Chips have been applied to model respiratory infections studied at Centers for Disease Control and Prevention, neurodegenerative conditions researched at the Alzheimer’s Association and Michael J. Fox Foundation, and hepatotoxicity assessments relevant to regulatory submissions at European Medicines Agency. Use cases extend to precision medicine collaborations with cancer centers such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, as well as toxicology screening for cosmetics evaluated under bans and regulations led by the European Union. The technology has influenced policy dialogues at the National Academies of Sciences, Engineering, and Medicine and contributed to research cited in journals including Nature, Science, and Cell.

Category:Biotechnology companies Category:Companies based in Boston, Massachusetts